Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), has stepped down, with market analysts forecasting a boost to the cell and ...

Investors braced for the Federal Reserve's next interest rate decision and earnings from tech giants Microsoft and Meta.

A controversial hematologist-oncologist who joined FDA this spring and quickly became its top regulator has left the ...